Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Paracetamol vs placebo Reconsultations Paracetamol (acetaminophen) or non‐steroidal anti‐inflammatory drugs, alone or combined, for pain relief in… (2023) · Cochrane | no estimate extracted | NR | No studies |
Paracetamol vs placebo Delayed antibiotic prescriptions Paracetamol (acetaminophen) or non‐steroidal anti‐inflammatory drugs, alone or combined, for pain relief in… (2023) · Cochrane | no estimate extracted | NR | No studies |
NSAIDs vs placebo hours Paracetamol (acetaminophen) or non‐steroidal anti‐inflammatory drugs, alone or combined, for pain relief in… (2023) · Cochrane | no estimate extracted | NR | No studies |
Triple therapy vs LABA/LAMA combination Outcomes (weighted · people with stable COPD Inhaled corticosteroids with combination inhaled long‐acting beta2‐agonists and long‐acting muscarinic… (2023) · Cochrane | no estimate extracted | NR | No studies |
Intensity of glycaemic control for women with gestational diabetes mellitus: tight glycaemic targets vs less‐tight glycaemic targets (child (as neonate, child, adult) outcomes) Neurosensory disability · children (as neonate, child, adult) of women with gestational diabetes mellitus Different intensities of glycaemic control for women with gestational diabetes mellitus (2023) · Cochrane | no estimate extracted | NR | No studies |
Intensity of glycaemic control for women with gestational diabetes mellitus: tight glycaemic targets vs less‐tight glycaemic targets (child (as neonate, child, adult) outcomes) Diabetes · children (as neonate, child, adult) of women with gestational diabetes mellitus Different intensities of glycaemic control for women with gestational diabetes mellitus (2023) · Cochrane | no estimate extracted | NR | No studies |
Intensity of glycaemic control for women with gestational diabetes mellitus: tight glycaemic targets vs less‐tight glycaemic targets (maternal outcomes) Subsequent development of type 2 diabetes · women with gestational diabetes mellitus Different intensities of glycaemic control for women with gestational diabetes mellitus (2023) · Cochrane | no estimate extracted | NR | No studies |
Intensity of glycaemic control for women with gestational diabetes mellitus: tight glycaemic targets vs less‐tight glycaemic targets (maternal outcomes) Return to pre‐pregnancy weight · women with gestational diabetes mellitus Different intensities of glycaemic control for women with gestational diabetes mellitus (2023) · Cochrane | no estimate extracted | NR | No studies |
Intensity of glycaemic control for women with gestational diabetes mellitus: tight glycaemic targets vs less‐tight glycaemic targets (maternal outcomes) Perineal trauma · women with gestational diabetes mellitus Different intensities of glycaemic control for women with gestational diabetes mellitus (2023) · Cochrane | no estimate extracted | NR | No studies |
Intensity of glycaemic control for women with gestational diabetes mellitus: tight glycaemic targets vs less‐tight glycaemic targets (maternal outcomes) Postnatal depression · women with gestational diabetes mellitus Different intensities of glycaemic control for women with gestational diabetes mellitus (2023) · Cochrane | no estimate extracted | NR | No studies |
Attention deficit hyperactivity disorder (ADHD)‐related drugs vs placebo Aggression · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging… Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD) (2023) · Cochrane | no estimate extracted | NR | No studies |
Antidepressants vs placebo Aggression · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging… Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD) (2023) · Cochrane | no estimate extracted | NR | No studies |
Neurohormones vs placebo Aggression · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging… Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD) (2023) · Cochrane | no estimate extracted | NR | No studies |
Neurohormones vs placebo Self Injury · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging… Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD) (2023) · Cochrane | no estimate extracted | NR | No studies |
Any‐treatment‐dose vitamin D (greater than 400 IU/day) vs supplemental‐dose vitamin D (less than 400 IU/day) Clinical relapse · people with active or inactive inflammatory bowel disease of any age Vitamin D for the treatment of inflammatory bowel disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Any‐treatment‐dose vitamin D (greater than 400 IU/day) vs supplemental‐dose vitamin D (less than 400 IU/day) Quality of life · people with active or inactive inflammatory bowel disease of any age Vitamin D for the treatment of inflammatory bowel disease (2023) · Cochrane | no estimate extracted | NR | No studies |
High‐treatment‐dose vitamin D (greater than 1000 IU/day) vs low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) Clinical response · people with active or inactive inflammatory bowel disease of any age Vitamin D for the treatment of inflammatory bowel disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Any‐treatment‐dose vitamin D (greater than 400 IU/day) vs supplemental‐dose vitamin D (less than 400 IU/day) Clinical response · people with active or inactive inflammatory bowel disease of any age Vitamin D for the treatment of inflammatory bowel disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Social activities vs usual care Consolidated sleep ‐ not measured · sleep disturbances in people with dementia Non‐pharmacological interventions for sleep disturbances in people with dementia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Social activities vs usual care Total wake time at night (minutes) ‐ not reported · sleep disturbances in people with dementia Non‐pharmacological interventions for sleep disturbances in people with dementia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Social activities vs usual care Number of nocturnal awakenings ‐ not reported · sleep disturbances in people with dementia Non‐pharmacological interventions for sleep disturbances in people with dementia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Light therapy vs usual care Consolidated sleep ‐ not measured · sleep disturbances in people with dementia Non‐pharmacological interventions for sleep disturbances in people with dementia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Social activities vs usual care Sleep onset latency ‐ not reported · sleep disturbances in people with dementia Non‐pharmacological interventions for sleep disturbances in people with dementia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Carer interventions vs usual care Consolidated sleep ‐ not measured · sleep disturbances in people with dementia Non‐pharmacological interventions for sleep disturbances in people with dementia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Carer interventions vs usual care Number of nocturnal awakenings ‐ not reported · sleep disturbances in people with dementia Non‐pharmacological interventions for sleep disturbances in people with dementia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Carer interventions vs usual care Sleep onset latency ‐ not reported · sleep disturbances in people with dementia Non‐pharmacological interventions for sleep disturbances in people with dementia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Multimodal interventions vs usual care Consolidated sleep ‐ not measured · sleep disturbances in dementia Non‐pharmacological interventions for sleep disturbances in people with dementia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Multimodal interventions vs usual care Sleep onset latency ‐ not reported · sleep disturbances in dementia Non‐pharmacological interventions for sleep disturbances in people with dementia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Physical activities vs usual care Consolidated sleep ‐ not measured · sleep disturbances in people with dementia Non‐pharmacological interventions for sleep disturbances in people with dementia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Starting short‐term prophylactic dose anticoagulation vs avoiding anticoagulation MACE ‐ not reported · survivors of stroke due to intracerebral haemorrhage Antithrombotic treatment after stroke due to intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Cilostazol vs aspirin All major occlusive vascular events ‐ not reported · adults within 180 days of non‐cardioembolic ischaemic stroke or transient ischaemic attack and a clinical history of… Antithrombotic treatment after stroke due to intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Cilostazol vs aspirin Functional status ‐ not reported · adults within 180 days of non‐cardioembolic ischaemic stroke or transient ischaemic attack and a clinical history of… Antithrombotic treatment after stroke due to intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Dextrose gel vs placebo Breastfeeding (exclusive after discharge) ‐ not reported (WHO 2008 definition (yes/no)) · newborn infants at risk of neonatal hypoglycaemia Oral dextrose gel to prevent hypoglycaemia in at‐risk neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Potassium paraaminobenzoate vs placebo Outcomes ( · men with acute (maximum of 12 months) Peyronie's disease with no prior treatment and no evidence of calcified plaques… Non‐surgical therapies for Peyronie's disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Injectional interferon alpha‐2B vs saline Treatment‐related adverse effects · men with chronic (≥ 12 months) Peyronie's disease (single plaque) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Injectional nicardipine vs saline Outcomes ( · men with chronic Peyronie's disease (plaques without calcification) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Injectional nicardipine vs saline Patient‐reported ability to have intercourse · men with chronic Peyronie's disease (plaques without calcification) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Injectional nicardipine vs saline Quality of life · men with chronic Peyronie's disease (plaques without calcification) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Injectional betamethasone vs saline Outcomes ( · men with Peyronie's disease (not defined) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Injectional betamethasone vs saline Patient‐reported ability to have intercourse · men with Peyronie's disease (not defined) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Injectional betamethasone vs saline Quality of life · men with Peyronie's disease (not defined) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Injectional betamethasone vs saline Degree of penile curvature · men with Peyronie's disease (not defined) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Injectional collagenase vs placebo Outcomes ( · men with Peyronie's disease (diagnosis of disease: at least 12 months, penile curvature: at least 30 degrees) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Injectional collagenase vs placebo Patient‐reported ability to have intercourse · men with Peyronie's disease (diagnosis of disease: at least 12 months, penile curvature: at least 30 degrees) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Injectional collagenase vs placebo Treatment‐related adverse effects · men with Peyronie's disease (diagnosis of disease: at least 12 months, penile curvature: at least 30 degrees) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Potassium paraaminobenzoate vs placebo Quality of life · men with acute (maximum of 12 months) Peyronie's disease with no prior treatment and no evidence of calcified plaques… Non‐surgical therapies for Peyronie's disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Injectional collagenase vs placebo Discontinuation from treatment · men with Peyronie's disease (diagnosis of disease: at least 12 months, penile curvature: at least 30 degrees) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Injectional collagenase vs placebo Outcomes ( · men with Peyronie's disease (diagnosis of disease: at least 12 months, penile curvature: at least 30 degrees) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Injectional collagenase vs placebo Patient‐reported ability to have intercourse · men with Peyronie's disease (diagnosis of disease: at least 12 months, penile curvature: at least 30 degrees) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Injectional verapamil vs saline (short‐term) Outcomes ( · men with Peyronie's disease (palpable plaque or pain) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane | no estimate extracted | NR | No studies |